Clinical Evaluation of Montelukast in Veterans With Gulf War Illness
Sponsor: Baylor College of Medicine • ClinicalTrials.gov ID: NCT05992311
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The study addresses the pre-clinical promise of Montelukast (MLK) for improving brain function in veterans with Gulf War Illness (GWI). MLK, a US Food and Drug administration (FDA)-approved drug for asthma, has shown efficacy in an animal model of GWI to improve cognitive and mood function through modulation of leukotriene signaling and suppression of neuroinflammation.
Interventions
-
Montelukast
(Drug)
This group will receive the montelukast treatment.
-
Placebo
(Other)
This group will receive a placebo pill instead of montelukast
Eligibility criteria
Conditions
Locations
- Michael E. DeBakey VA Medical Center — Houston, Texas, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record